Aa
A
A
Close
Avatar universal
PARC rule .... Comments needed
“PARC rule” has been recently validated and published as
a stopping rule at week 12, using HBsAg and HBV DNA for
HBeAg-negative, genotype D patients treated with Peg-IFN
α-2a. According to this rule, we can identify early, with a NPV
of 100%, all CHB, HBeAg-negative, genotype D patients that
will not achieve SVR aer 48 or 96 weeks of treatment with
Peg-IFN α-2a [2]. e dierence between the results obtained
in our study (a NPV of 86% for absence of SVR and a PPV of
80% for those who achieved SVR) and the results published
in the validation trial conducted by Rijckborst et al, can be
explained by the inclusion in statistical analysis of both types
of patients, HBeAg positive and negative, and no stratication
of patients according to viral genotype
Cancel
1 Answers
Page 1 of 1
Avatar universal
Hi, the rule tries to validate the duration of therapy with PEG-IFN. It states that in HBeAg-negative patients the sustained response to therapy is not present beyond 12 weeks. So, in these patients therapy beyond 12 weeks with PEG-IFN is not indicated. Regards.
Comment
Cancel
Comment
Avatar universal
Comment
Comment
Submit Comment
Your Answer
Avatar universal
Answer
Know how to answer? Tap here to leave your answer...
Answer
Submit Answer
A
A
Blank
Weight Tracker
Weight Tracker
Start Tracking Now
Hepatitis B Community Resources